Do patients with schizophrenia or bipolar disorder always have to...

@psycheureka
Psychiatry Excellence@psycheureka
15 views Aug 27, 2025 ~2 min read
Advertisement
1
Do patients with schizophrenia or bipolar disorder always have to be heavily sedated when agitated?

A new study (Mashaw, 2025) highlights that agitation isn’t just disruptive. It signals distress, resistance to care, and safety risks.

Here are emerging treatments that can calm without over-sedation, helping you manage agitation more safely and effectively in daily practice. 👇🧵
Media image
2
Agitation is one of the most urgent psychiatric emergencies.

Traditional medications often calm quickly but bring significant risks:

● Extrapyramidal symptoms (EPS)

● Respiratory depression

● Falls, fractures, cognitive impairment, and over-sedation

Clinicians need safer pathways that preserve engagement.

So what are the new treatments that can reduce these risks?
3
Sublingual Dexmedetomidine

Sublingual film, FDA-approved (2022).

● Rapid calming, non-invasive

● Sedation without respiratory depression

● May cause hypotension, bradycardia, somnolence

A practical option when patients resist injections.
4
Subcutaneous Olanzapine

Alternative to IM haloperidol.

● Faster onset, lower EPS risk

● Evidence still limited, mostly from delirium cohorts

● Well-tolerated, fewer injection complications

Broadens antipsychotic options in acute agitation.
5
Ketamine

Ultra-rapid option in severe or prehospital agitation.

● Fast onset, effective in specific contexts

● May cause dissociation

● Avoid in schizophrenia due to the risk of psychiatric exacerbation

● Requires close monitoring

Best reserved for extreme cases with safeguards in place.
6
Gabapentinoids

Gabapentin / Pregabalin.

● May help with anxiety, insomnia, chronic dysregulation

● Not effective in acute agitation

● Sedation may worsen negative symptoms

Use is limited in emergency psychiatry.
7
Investigational Options

Still early-stage:

● Intranasal delivery systems (e.g., olanzapine) → promising but limited evidence

● Cannabinoids → potential role, but regulatory and dosing barriers

Not FDA-approved; not yet ready for routine practice.
8
How can these treatments guide care?

● Mild–moderate → sublingual dexmedetomidine (non-invasive, calming)

● Moderate–severe → subcutaneous olanzapine (faster, lower EPS vs IM haloperidol)

● Extreme/prehospital → ketamine (with monitoring; avoid in schizophrenia when possible)

● Gabapentinoids / CBD → not acute tools; limited to chronic states

A graded approach helps match treatment to clinical need.
9
Psych Scene Tip 💡

Start with de-escalation whenever possible.

If medication is needed:

● Begin with a single agent

● Combine only when justified

● Document rationale and review timeframe

This reduces compounded risks and keeps care patient-centred.
10
Want to refine how you manage agitation in schizophrenia?

Dive deeper into diagnosis, staging, and evidence-based treatment with our course, “Schizophrenia: Advanced Clinical Approaches & Training for Psychiatrists” on The Academy:

psychscene.co/4lLKPHG
Actions
What You Can Do
  • Export as PDF or Markdown
  • Batch Export to Notion
  • Bookmark & Highlight
  • Screenshot Tweet
Create Free Account

Includes 7-day Premium trial

Advertisement